At Neurocrine Biosciences, our responsibilities reach beyond office walls. We’re committed to the patients we serve and their communities.

A family of four on a walk at the beach

Patient Access

Improving the lives and well-being of patients
We understand that patient access is a priority because discovering and developing new medicines alone is not enough. Important medical advancements can only change lives when they reach patients who need relief.
We determine the price of our medicines based on their value and impact to patients, families, care partners, providers, insurers, and society as a whole. We adhere to the highest ethical and compliance standards and are guided by the following principles:
Green icon of a stethoscope
Improving the lives and well-being of patients
Green icon of an arrow pointing down
Maximizing access and reducing out-of-pocket costs for eligible patients
Green icon of a bottle of prescription medicine
Striving to reduce obstacles for patients to fill a prescription or undergo treatment
Green icon of scientific flasks
Fueling the discovery and development of life-changing medicines

Expanded Access to Neurocrine Investigational Medicines

Expanded Access Program (EAP)
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options.

Clinical trials are an essential part of the development and registration of innovative medicines, and critical to making those innovative medicines available to underserved patients, families, and caregivers.  In the normal course of researching, developing, and marketing medicines, Neurocrine works with Healthcare Professionals (HCPs), patients, and healthy volunteers to conduct clinical trials evaluating the safety and efficacy of investigational medicines prior to pursuing regulatory approval. While administration within the framework of controlled clinical research is optimal, there may be occasions when it is in the interest of some patients to have access to investigational medicines when enrollment in a clinical trial is not possible.
Where individuals have a serious or life-threatening disease or condition for which Neurocrine has a potential therapy and where all alternative treatment options, including enrolling in available clinical trials are not suitable, “expanded access” may be a suitable option. Neurocrine will carefully review all expanded access requests submitted by a physician or qualified HCP on a case-by-case basis.
To access the Neurocrine Biosciences Expanded Access to Investigational Medicines policy, including application submission directions for physicians or qualified HCPs, please click here.

Environmental, Social, & Governance (ESG)

Committing to ESG principles that align with our purpose
Our ESG programs are consistent with our purpose, which we fulfill through effective management of critical environmental, social, and governance principles that are fundamental to our business.

Our ESG initiatives, which are closely aligned with those identified by the Sustainability Accounting Standards Board (SASB) for the biotechnology industry, focus on the following commitments:
Green icon of a check mark
Operate with the highest standards of business ethics
Green icon of street signs on a post
Adhere to the highest product quality and safety standards
Green icon of three people in a group huddle
Invest in our people and communities
Green icon of an arrow pointing down
Minimize our impact on the environment